Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VVOS Vivos Therapeutics

Pre-Mkt 01-15 08:22:11 EST

2.09

+0.14

+7.18%

盘前2.16

+0.07+3.23%

08:18 EST

High2.15	Low1.96	Vol115.81K
Open2.00	D1 Closing1.95	Amplitude9.74%
Mkt Cap19.38M	Tradable Cap14.46M	Total Shares9.27M
T/O236.80K	T/O Rate1.67%	Tradable Shares6.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VVOS","market":"US","secType":"STK","nameCN":"Vivos Therapeutics","latestPrice":2.09,"timestamp":1768424400000,"preClose":1.95,"halted":0,"volume":115811,"hourTrading":{"tag":"盘前","latestPrice":2.1575,"preClose":2.09,"latestTime":"08:18 EST","volume":673,"amount":1460.3975495,"timestamp":1768483136904},"delay":0,"floatShares":6917500,"shares":9274800,"eps":-1.90536,"marketStatus":"Pre-Mkt","change":0.14,"latestTime":"01-15 08:22:11 EST","open":2,"high":2.15,"low":1.9601,"amount":236802.11021899997,"amplitude":0.097385,"askPrice":2.2,"askSize":1100,"bidPrice":1.88,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.90536,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768487400000},"marketStatusCode":1,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":2.09,"preHourTrading":{"tag":"盘前","latestPrice":2.1575,"preClose":2.09,"latestTime":"08:18 EST","volume":673,"amount":1460.3975495,"timestamp":1768483136904},"postHourTrading":{"tag":"盘后","latestPrice":2.04,"preClose":2.09,"latestTime":"19:51 EST","volume":860,"amount":1733.5112,"timestamp":1768438304997},"volumeRatio":0.9041447752542281,"impliedVol":2.594,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VVOS/tweets","defaultTab":"tweets","newsList":[{"id":"2602375818","title":"Alliance Global Partners Sticks to Its Hold Rating for Vivos Therapeutics (VVOS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375818","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602375818?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:35","pubTimestamp":1767962138,"startTime":"0","endTime":"0","summary":"Alliance Global Partners analyst maintained a Hold rating on Vivos Therapeutics today and set a price target of $2.50. The word on The Street in ge...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-sticks-to-its-hold-rating-for-vivos-therapeutics-vvos-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-sticks-to-its-hold-rating-for-vivos-therapeutics-vvos-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS"],"gpt_icon":0},{"id":"2591298790","title":"Vivos Therapeutics Opens New Sleep Center in Auburn Hills, Michigan","url":"https://stock-news.laohu8.com/highlight/detail?id=2591298790","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591298790?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:45","pubTimestamp":1765892730,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Inc., a leader in medical devices and healthcare services for sleep-related breathing disorders, has announced the grand opening of a new sleep testing and treatment center near Detroit in Auburn Hills, Michigan. This expansion is part of Vivos' national growth strategy, leveraging contractual alliances with local sleep clinics such as MISleep Solutions, LLC. The new center will offer Vivos' FDA-cleared diagnostic and therapeutic products for obstructive sleep apnea , aiming to bring innovative treatment options to a broader patient base while providing additional revenue streams for both Vivos and its affiliated providers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLb7LVW7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2095319765.USD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4112","BK4588","LU2210150020.SGD","LU0314104364.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","VVOS","NDAQ","BK4196","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2591627600","title":"Vivos Therapeutics Executives Join Water Tower Research Online Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2591627600","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591627600?lang=en_us&edition=fundamental","pubTime":"2025-12-16 06:30","pubTimestamp":1765837810,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Inc. will participate in an online fireside chat with Water Tower Research on December 16, 2025, at 11:00 am ET. CEO Kirk Huntsman and CFO Brad Amman will discuss the company's strategic business model pivot, operational execution, market opportunity, competitive environment, and growth and financial strategies. The event is listen-only, and a replay will be available for 30 days in the Investor Relations section of the Vivos website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL2RJxtM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","BK4588","SG9999014039.USD","BK4112","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","BK4196","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014021.USD","BK4585","VVOS"],"gpt_icon":0},{"id":"2589485048","title":"Vivos Therapeutics Secures $2.1 Million Unsecured Loan from Avondale Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589485048","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589485048?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:13","pubTimestamp":1764972814,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc. has entered into a new unsecured debt financing arrangement with Avondale Capital, LLC, an affiliate of Streeterville Capital, LLC. Under the terms of the Note Purchase Agreement dated December 5, 2025, Vivos issued a promissory note with an original principal amount of $2,093,340, which includes an original issue discount and transaction costs. The company received approximately $1.5 million in gross proceeds from the note, which is not convertible into common stock and does not bear interest unless an event of default occurs. Weekly payments of $69,778 will begin on December 12, 2025, and the company may prepay the note without penalty, with an additional principal reduction offered for repayment by January 4, 2026. The note is guaranteed by Vivos's wholly-owned subsidiary, Airway Integrated Management Company, LLC. Proceeds from the financing will be used for working capital and general corporate purposes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDLxWPQx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WNWG","BK4196","BK4213","VVOS"],"gpt_icon":0},{"id":"2588436200","title":"Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2588436200","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588436200?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:56","pubTimestamp":1764762960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VVOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 06:56 ET (11:56 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"gpt_icon":0},{"id":"2585866122","title":"Vivos Therapeutics Reports Strong Q3 Growth Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2585866122","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585866122?lang=en_us&edition=fundamental","pubTime":"2025-11-22 08:05","pubTimestamp":1763769951,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc. (($VVOS)) has held its Q3 earnings call. Read on for the main highlights of the call. Vivos Therapeutics, Inc. recently he...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-reports-strong-q3-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-reports-strong-q3-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2584011959","title":"Vivos Therapeutics Reports Revenue Growth Amid Strategic Shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2584011959","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584011959?lang=en_us&edition=fundamental","pubTime":"2025-11-20 11:56","pubTimestamp":1763611010,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc. ( ($VVOS) ) has released its Q3 earnings. Here is a breakdown of the information Vivos Therapeutics, Inc. presented to its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-reports-revenue-growth-amid-strategic-shift?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-reports-revenue-growth-amid-strategic-shift?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS"],"gpt_icon":0},{"id":"2584762699","title":"Vivos Therapeutics Reports 78% Sequential Revenue Growth in Third Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584762699","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584762699?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:45","pubTimestamp":1763588749,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Inc. reported significant revenue growth for the third quarter of 2025, with a 78% sequential quarter-over-quarter increase and a 76% rise compared to the same period in the previous year. The company attributed the growth to its strategic shift from relying on a dental industry distribution channel to acquiring and affiliating with medical sleep practices and testing centers, highlighted by the June 2025 acquisition of The Sleep Center of Nevada. Further details and financial results for the three and nine months ended September 30, 2025, are available in the company's Quarterly Report on Form 10-Q filed with the SEC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original conte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL404MmW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2584768479","title":"Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2584768479","media":"Reuters","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584768479?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:30","pubTimestamp":1763587841,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Q3 revenue rises, helped by SCN acquisitionOverviewVivos Q3 2025 revenue rises 76% yr/yr, driven by SCN acquisitionCompany's gross margin declines to 58% from 60% due to pricing dis","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL1N3WV16C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2584761089","title":"Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584761089","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584761089?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:30","pubTimestamp":1763587818,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $6.78M, consensus $4.71M. Kirk Huntsman, Vivos’ chairman and CEO, stated, “We are very pleased to announce that our third quarte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-reports-q3-eps-49c-consensus-51c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-reports-q3-eps-49c-consensus-51c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS"],"gpt_icon":0},{"id":"2584975273","title":"BRIEF-Vivos Therapeutics Q3 Net Income USD -5.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584975273","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584975273?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:20","pubTimestamp":1763587246,"startTime":"0","endTime":"0","summary":"BRIEF-Vivos Therapeutics Q3 Net Income USD -5.4 Million\n\n\nNov 19 (Reuters) - Vivos Therapeutics Q3 operating income USD -4.734 million.\n\nQ3 gross profit USD 3.937 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nPLX7430DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2584975758","title":"Vivos Therapeutics Inc - Qtrly Net Loss per Share Basic and Diluted $0.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2584975758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584975758?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:20","pubTimestamp":1763587201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nPLX7430DA:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2584975228","title":"Vivos Therapeutics Q3 Gross Profit USD 3.937 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584975228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584975228?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:20","pubTimestamp":1763587201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nPLX7430DA:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2584097573","title":"Vivos Therapeutics Inc - Revenue $6.8 Mln in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584097573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584097573?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:20","pubTimestamp":1763587201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nPLX7430DA:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2584897544","title":"Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584897544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584897544?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:20","pubTimestamp":1763587200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA2SFGSL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2584975997","title":"Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2584975997","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584975997?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:08","pubTimestamp":1763586495,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.41) by 18.07 percent. This is a 22.5 percent decrease over losses of $(0.40) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48962626/vivos-therapeutics-q3-eps-0-49-misses-0-41-estimate-sales-6-783m-beat-4-686m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"gpt_icon":0},{"id":"2584944329","title":"Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2584944329","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584944329?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:30","pubTimestamp":1763559000,"startTime":"0","endTime":"0","summary":"Call scheduled for today, Wednesday, November 19, 2025, at 5:00 pm ETLITTLETON, Colo., Nov.  19, 2025  (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3190932/0/en/Vivos-Therapeutics-Schedules-Release-of-Third-Quarter-2025-Financial-Results-and-Conference-Call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4196","CARE","VVOS"],"gpt_icon":0},{"id":"2584607623","title":"Vivos Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2584607623","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584607623?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:42","pubTimestamp":1763383320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VVOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 07:42 ET (12:42 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2584097642","title":"Vivos Therapeutics initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2584097642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584097642?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:15","pubTimestamp":1763378144,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Vivos Therapeutics (VVOS) with a Buy rating and $7 price target Vivos is a commercial-stage medical device co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-initiated-with-a-buy-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-initiated-with-a-buy-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2584642196","title":"Vivos Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642196","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642196?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:11","pubTimestamp":1763377861,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nAZN4QTUN5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","VVOS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivos.com","stockEarnings":[{"period":"1week","weight":-0.0813},{"period":"1month","weight":0.0347},{"period":"3month","weight":-0.2768},{"period":"6month","weight":-0.6409},{"period":"1year","weight":-0.587},{"period":"ytd","weight":0.0296}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.243872},{"month":2,"riseRate":0.4,"avgChangeRate":-0.055487},{"month":3,"riseRate":0,"avgChangeRate":-0.220324},{"month":4,"riseRate":0.4,"avgChangeRate":-0.155798},{"month":5,"riseRate":0.4,"avgChangeRate":-0.052997},{"month":6,"riseRate":0.6,"avgChangeRate":0.052001},{"month":7,"riseRate":0.4,"avgChangeRate":-0.104292},{"month":8,"riseRate":0.6,"avgChangeRate":0.170604},{"month":9,"riseRate":0,"avgChangeRate":-0.252021},{"month":10,"riseRate":0.2,"avgChangeRate":-0.105489},{"month":11,"riseRate":0.4,"avgChangeRate":1.251693},{"month":12,"riseRate":0.2,"avgChangeRate":-0.12992}],"exchange":"NASDAQ","name":"Vivos Therapeutics","nameEN":"Vivos Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vivos Therapeutics,VVOS,Vivos Therapeutics股票,Vivos Therapeutics股票老虎,Vivos Therapeutics股票老虎国际,Vivos Therapeutics行情,Vivos Therapeutics股票行情,Vivos Therapeutics股价,Vivos Therapeutics股市,Vivos Therapeutics股票价格,Vivos Therapeutics股票交易,Vivos Therapeutics股票购买,Vivos Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction